Date: 2015-04-16
Type of information: Presentation of results at a congress
phase:
Announcement: presentation of results at the 2015 European Lung Cancer Conference (ELCC) being held in Geneva
Company: Integragen (France)
Product: miR-31-3p biomarker
Action
mechanism: biomarker. IntegraGen obtained the exclusive license for the worldwide rights for the miR-31-3p biomarker from the Paris Descartes University, INSERM, the Centre National de la Recherche Scientifique, and the Assistance Publique - Hopitaux de Paris (AP-HP), all leading French academic institutions which, along with IntegraGen, are co-owners of the patent.
Disease: advanced stage non-small cell lung cancer (NSCLC)
Therapeutic area: Cancer - Oncology
Country:
Trial details:
Latest
news: * On April 16, 2015, IntegraGen announced that it presented data on the microRNA biomarker, miR-31-3p, during the 2015 European Lung Cancer Conference (ELCC) being held in Geneva, Switzerland. Based on a study of patients with advanced lung cancer, the data presented demonstrates that the expression of miR-31-3p is correlated with the histological type of the lung tumor, with a higher expression of the biomarker in mucinous type, and also identifies patients with a shorter progression-free survival. The results also indicate that miR-31-3p is associated with overall survival and disease control rate in a subgroup of patients with advanced non-small cell lung cancer (NSCLC) treated with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI). The data presented was based on a post-hoc analysis of patients enrolled in two prospective, randomized controlled phase II trials of EGFR TKIs in patients with non-resectable pneumonic adenocarcinoma which were conducted by the French Cooperative Thoracic Intergroup (IFCT). “With the increasing use of EGFR TKIs in patients with lung cancer there is a need to identify molecular markers which can help guide clinicians to treat patients who are more likely to benefit from this class of drugs,” stated Professor Jacques Cadranel, a Member of the IFCT Scientific Council and coordinating investigator for both the IFCT-0401 and IFCT-0504 clinical trials from which samples for the study of miR- 31-3p were obtained. \"The results of our study provide initial evidence that patients with low expression levels of miR-31-3p may preferentially benefit from EGFR TKI therapy, especially patients with nonmucinous
type adenocarcinoma of the lung.”
